Which has better earnings & valuation, DXCM or HAE?

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 7.11 $836.30M $2.53 34.74 Haemonetics $1.33B 3.51 $97.31M $2.04 50.49

Is DXCM or HAE more profitable?

DexCom has a net margin of 20.12% compared to Haemonetics' net margin of 7.12%. DexCom's return on equity of 35.94% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Haemonetics 7.12% 27.55% 9.65%

Does the media refer more to DXCM or HAE?

In the previous week, DexCom had 5 more articles in the media than Haemonetics. MarketBeat recorded 12 mentions for DexCom and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.27 beat DexCom's score of 1.19 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HQY or HAE?

In the previous week, HealthEquity had 1 more articles in the media than Haemonetics. MarketBeat recorded 8 mentions for HealthEquity and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.27 beat HealthEquity's score of 0.99 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, HAE or LNTH?

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.51 $97.31M $2.04 50.49 Lantheus $1.54B 4.27 $233.56M $4.14 24.39

Is HAE or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Haemonetics' net margin of 7.12%. Lantheus' return on equity of 28.10% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% Lantheus 17.69% 28.10% 14.35%

Does the media prefer HAE or LNTH?

In the previous week, Haemonetics had 4 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Haemonetics and 3 mentions for Lantheus. Lantheus' average media sentiment score of 1.44 beat Haemonetics' score of 1.27 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HAE or PODD?

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.51 $97.31M $2.04 50.49 Insulet $2.71B 3.78 $247.10M $5.35 27.57

Is HAE or PODD more profitable?

Insulet has a net margin of 12.29% compared to Haemonetics' net margin of 7.12%. Insulet's return on equity of 29.29% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% Insulet 12.29% 29.29% 13.31%

Does the media favor HAE or PODD?

In the previous week, Insulet had 3 more articles in the media than Haemonetics. MarketBeat recorded 10 mentions for Insulet and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.27 beat Insulet's score of 0.89 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, HAE or QTRX?

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.51 $97.31M $2.04 50.49 Quanterix $138.90M 0.92 -$107.15M -$2.63 N/A

Is HAE or QTRX more profitable?

Haemonetics has a net margin of 7.12% compared to Quanterix's net margin of -80.25%. Haemonetics' return on equity of 27.55% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% Quanterix -80.25% -26.09% -19.03%

Does the media prefer HAE or QTRX?

In the previous week, Haemonetics had 6 more articles in the media than Quanterix. MarketBeat recorded 7 mentions for Haemonetics and 1 mentions for Quanterix. Quanterix's average media sentiment score of 1.84 beat Haemonetics' score of 1.27 indicating that Quanterix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quanterix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Haemonetics (HAE) Competitors

$103.00 +0.08 (+0.08%)

As of 09/4/2026 03:58 PM Eastern

Compare

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

Should you buy Haemonetics stock or one of its competitors? Haemonetics's main competitors and comparable companies include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Haemonetics compare to DexCom?

DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 2.1% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DexCom has a net margin of 20.12% compared to Haemonetics' net margin of 7.12%. DexCom's return on equity of 35.94% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Haemonetics	7.12%	27.55%	9.65%

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	7.11	$836.30M	$2.53	34.74
Haemonetics	$1.33B	3.51	$97.31M	$2.04	50.49

DexCom currently has a consensus target price of $88.71, suggesting a potential upside of 0.92%. Haemonetics has a consensus target price of $99.78, suggesting a potential downside of 3.13%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

DexCom has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, DexCom had 5 more articles in the media than Haemonetics. MarketBeat recorded 12 mentions for DexCom and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.27 beat DexCom's score of 1.19 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Haemonetics on 13 of the 17 factors compared between the two stocks.

How does Haemonetics compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.6% of HealthEquity shares are held by company insiders. Comparatively, 2.1% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HealthEquity has higher earnings, but lower revenue than Haemonetics. HealthEquity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	6.05	$215.20M	$2.77	34.68
Haemonetics	$1.33B	3.51	$97.31M	$2.04	50.49

HealthEquity has a net margin of 17.36% compared to Haemonetics' net margin of 7.12%. Haemonetics' return on equity of 27.55% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.36%	15.33%	9.51%
Haemonetics	7.12%	27.55%	9.65%

HealthEquity has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

HealthEquity presently has a consensus target price of $111.87, suggesting a potential upside of 16.44%. Haemonetics has a consensus target price of $99.78, suggesting a potential downside of 3.13%. Given HealthEquity's stronger consensus rating and higher possible upside, analysts clearly believe HealthEquity is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, HealthEquity had 1 more articles in the media than Haemonetics. MarketBeat recorded 8 mentions for HealthEquity and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.27 beat HealthEquity's score of 0.99 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HealthEquity and Haemonetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Haemonetics compare to Lantheus?

Haemonetics (NYSE:HAE) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Haemonetics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.51	$97.31M	$2.04	50.49
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.39

Lantheus has a net margin of 17.69% compared to Haemonetics' net margin of 7.12%. Lantheus' return on equity of 28.10% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Lantheus	17.69%	28.10%	14.35%

Haemonetics currently has a consensus price target of $99.78, indicating a potential downside of 3.13%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.07%. Given Lantheus' higher possible upside, analysts plainly believe Lantheus is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Haemonetics had 4 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Haemonetics and 3 mentions for Lantheus. Lantheus' average media sentiment score of 1.44 beat Haemonetics' score of 1.27 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Lantheus beats Haemonetics on 9 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Insulet?

Haemonetics (NYSE:HAE) and Insulet (NASDAQ:PODD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

99.7% of Haemonetics shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.51	$97.31M	$2.04	50.49
Insulet	$2.71B	3.78	$247.10M	$5.35	27.57

In the previous week, Insulet had 3 more articles in the media than Haemonetics. MarketBeat recorded 10 mentions for Insulet and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.27 beat Insulet's score of 0.89 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Insulet has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Insulet has a net margin of 12.29% compared to Haemonetics' net margin of 7.12%. Insulet's return on equity of 29.29% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Insulet	12.29%	29.29%	13.31%

Haemonetics currently has a consensus price target of $99.78, suggesting a potential downside of 3.13%. Insulet has a consensus price target of $195.40, suggesting a potential upside of 32.49%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Insulet beats Haemonetics on 11 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Quanterix?

Haemonetics (NYSE:HAE) and Quanterix (NASDAQ:QTRX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Haemonetics has a net margin of 7.12% compared to Quanterix's net margin of -80.25%. Haemonetics' return on equity of 27.55% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Quanterix	-80.25%	-26.09%	-19.03%

Haemonetics presently has a consensus target price of $99.78, indicating a potential downside of 3.13%. Quanterix has a consensus target price of $3.00, indicating a potential upside of 11.52%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Haemonetics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Haemonetics had 6 more articles in the media than Quanterix. MarketBeat recorded 7 mentions for Haemonetics and 1 mentions for Quanterix. Quanterix's average media sentiment score of 1.84 beat Haemonetics' score of 1.27 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quanterix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.51	$97.31M	$2.04	50.49
Quanterix	$138.90M	0.92	-$107.15M	-$2.63	N/A

Summary

Haemonetics beats Quanterix on 14 of the 17 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HAE vs. The Competition

Export

Metric	Haemonetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$4.69B	$5.66B	$7.21B	$23.59B
Dividend Yield	N/A	1.76%	2.54%	3.73%
P/E Ratio	50.49	25.99	273.84	29.33
Price / Sales	3.51	72.95	625.56	19.82
Price / Cash	13.58	33.42	28.92	19.95
Price / Book	6.01	6.10	11.01	4.83
Net Income	$97.31M	$150.94M	$3.49B	$1.07B
7 Day Performance	0.27%	-1.07%	1.63%	0.43%
1 Month Performance	17.71%	1.02%	4.42%	-0.78%
1 Year Performance	89.54%	9.91%	24.21%	12.82%

Haemonetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HAE Haemonetics	2.983 of 5 stars	$103.00 +0.1%	$99.78 -3.1%	+89.5%	$4.69B	$1.33B	50.49	3,009
DXCM DexCom	4.1718 of 5 stars	$91.06 +0.3%	$88.71 -2.6%	+9.2%	$34.27B	$4.66B	35.99	11,000	Positive News Analyst Upgrade
HQY HealthEquity	4.3928 of 5 stars	$96.54 +0.2%	$111.87 +15.9%	+5.0%	$7.97B	$1.31B	34.85	2,814	Analyst Downgrade
LNTH Lantheus	3.7992 of 5 stars	$100.96 +0.2%	$108.11 +7.1%	+84.4%	$6.58B	$1.54B	24.39	1,193	Positive News
PODD Insulet	4.2089 of 5 stars	$148.66 +2.4%	$195.40 +31.4%	-57.7%	$10.07B	$2.71B	27.79	5,400	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HAE) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Summary

How does Haemonetics compare to HealthEquity?

Summary

How does Haemonetics compare to Lantheus?

Summary

How does Haemonetics compare to Insulet?

Summary

How does Haemonetics compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Do institutionals & insiders have more ownership in DXCM or HAE?

Is DXCM or HAE more profitable?

Which has better earnings & valuation, DXCM or HAE?

Do analysts recommend DXCM or HAE?

Which has more volatility and risk, DXCM or HAE?

Does the media refer more to DXCM or HAE?

Summary

How does Haemonetics compare to HealthEquity?

Do institutionals and insiders have more ownership in HQY or HAE?

Which has better valuation and earnings, HQY or HAE?

Is HQY or HAE more profitable?

Which has more risk and volatility, HQY or HAE?

Do analysts rate HQY or HAE?

Does the media refer more to HQY or HAE?

Summary

How does Haemonetics compare to Lantheus?

Which has more volatility & risk, HAE or LNTH?

Which has better earnings and valuation, HAE or LNTH?

Is HAE or LNTH more profitable?

Do analysts rate HAE or LNTH?

Does the media prefer HAE or LNTH?

Do insiders & institutionals hold more shares of HAE or LNTH?

Summary

How does Haemonetics compare to Insulet?

Do insiders & institutionals believe in HAE or PODD?

Which has stronger valuation and earnings, HAE or PODD?

Does the media favor HAE or PODD?

Which has more risk and volatility, HAE or PODD?

Is HAE or PODD more profitable?

Do analysts rate HAE or PODD?

Summary

How does Haemonetics compare to Quanterix?

Is HAE or QTRX more profitable?

Do analysts rate HAE or QTRX?

Which has more volatility & risk, HAE or QTRX?

Does the media prefer HAE or QTRX?

Do institutionals & insiders believe in HAE or QTRX?

Which has stronger earnings and valuation, HAE or QTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools